Last $13.60 USD
Change Today -1.78 / -11.57%
Volume 703.7K
SCMP On Other Exchanges
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - $16.54
52 Week Low
07/31/14 - $5.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. It is developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its collaboration and license agreement with Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; and opioid-induced constipation in adults with chronic non-cancer pain. It also provides AMITIZA in Japan through its collaboration and license agreement with Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, the company markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. Its pipeline also includes AMITIZA, which is in Phase III trial for pediatric functional constipation. The company’s other pipeline products consist of IV Ion Channel Activator, which is in Phase IIa clinical trial for the treatment of Lumbar spinal stenosis; PO Ion Channel Activator that is in Phase Ia trial for the treatment of Lumbar spinal stenosis; and cobiprostone, which has completed Phase I clinical development for the treatment of oral mucositis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

77 Employees
Last Reported Date: 03/12/14
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $593.5K
Chief Financial Officer
Total Annual Compensation: $273.9K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $338.9K
Compensation as of Fiscal Year 2013.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals, Inc. and R-Tech Ueno, Ltd. Enter License Agreement with Par Pharmaceutical

Sucampo Pharmaceuticals, Inc. and R-Tech Ueno, Ltd. have entered into a stipulation and license agreement with Par Pharmaceutical, Inc. Under the terms of the agreement, in limited circumstances, Sucampo or RTU will grant PPI a license for a generic version of the RESCULA(R) (unoprostone isopropyl ophthalmic solution) 0.15% product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Under such license, PPI will split with Sucampo the gross profits of the generic or authorized generic version sold during the term of the agreement, which continues until the last of Sucampo patents relating to RESCULA have expired. In the event PPI elects to launch an authorized generic, Sucampo will supply PPI under the terms of a manufacturing and supply agreement at a negotiated price.

Sucampo Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 02:40 PM

Sucampo Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 02:40 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Peter S. Greenleaf, Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee, Silvia Taylor, Senior Vice President of Investor Relations and Corporate Communications.

Sucampo Pharmaceuticals Appoints Andrew Smith as CFO

Sucampo Pharmaceuticals, Inc. announced the appointment of Andrew Smith, FCMA, CGMA to Chief Financial Officer. Mr. Smith previously served as Sucampo's Vice President, Operations & Finance and has over 30 years of financial and accounting experience within the pharmaceutical, biotechnology and medical device industries in companies ranging from start-ups to multinationals, as well as in public accounting. Mr. Smith joined Sucampo in 2011 as Principal Accounting Officer and was most recently Vice President, Operations and Finance. Prior to joining Sucampo, Mr. Smith was Finance Director and Company Secretary for Retroscreen Virology Ltd., and the Finance Director and Company Secretary of Clearlab Europe, a division of 1-800 Contacts Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $13.60 USD -1.78

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $6.35 USD +0.22
Momenta Pharmaceuticals Inc $13.98 USD +0.33
Pernix Therapeutics Holdings Inc $10.77 USD +0.04
Progenics Pharmaceuticals Inc $6.65 USD +0.14
Sagent Pharmaceuticals Inc $27.88 USD +0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation SCMP Industry Range
Price/Earnings 100.0x
Price/Sales 6.7x
Price/Book 9.4x
Price/Cash Flow 122.4x
TEV/Sales 5.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at